The report will be delivered in 2-3 business days.

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth And Change

Starting Price : $ 4000.00 $3200.00 | Pages : 150 | Published : October 2020 | SKU CODE : 7741 | Format :


The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules such as Humira, Remicade and Enbrel, respectively.

The global adalimumab, infliximab, and etanercept market is expected to grow from $2.2 billion in 2019 to $2.27 billion in 2020 at a compound annual growth rate (CAGR) of 3.24%. The slow growth is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $7.50 billion in 2023 at a CAGR of 48.94%.

North America was the largest region in the adalimumab, infliximab, and etanercept market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

The patent expiry of branded drugs allows biosimilars to enter the market. For instance, in 2016, United States FDA approved inflectra, developed by Hospira (a Pfizer Inc company) for the treatment of various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, plaque psoriasis, after the patent expiry of branded drug Remicade. Similarly, Amgen`s Enbrel had its patent expired in the EU in 2015 and with the expiry of the patent, Benepali (a biosimilar of Enmbrel) was approved by the European Commission in 2016. Humira`s patent expired in December 2016 and its biosimilars were made available in the market. FDA has recently (July 2020) approved Hulio, the sixth biosimilar of Humira. Therefore, the patent expiry of branded biologic drugs such as Humira, Enbrel and Remicade will drive the biosimilar market.

The patent extension of Humira (adalimumab) will hamper the Humira biosimilar market. The patent extension is a strategy to compete with generic and biosimilar products after patent termination. For instance, the patents of Humira, the branded biologic drug manufactured by AbbVie, expired in 2016 in the US and 2017 in the EU. AbbVie obtained Supplementary Protection Certificates (SPCs) that provided protection in Europe until 16 October 2018. AbbVie received a patent extension for Humira till 2023 in the US. In pursuit of patent extension, AbbVie also had settlements with Amgen, Samsung Bioepis, and Mylan to protect Humira sales in the United States. The patent extension of Humira is anticipated to hinder its biosimilars market growth.

The brand versions of biosimilar drugs are of high costs, which are now being replaced with biosimilar versions upon their patent’s expiry. The cost of branded biologic drugs almost doubled in recent years. For instance, the cost of Humira, the top-selling drug, increased to more than $38,000 in 2018 from $19,000 in 2012. The shift to low-cost biosimilar drugs is mainly because there are no clinically relevant differences in safety and efficacy between the biosimilars and originator biologics. The Danish health care system switched almost entirely to adalimumab biosimilars after the patent on the original adalimumab product, Humira, expired in October 2018. The switch to biosimilars led to an 82% decrease in costs for the medication.

In February 2016, Sandoz acquired development and commercialization rights of PF-06438179 (biosimilar infliximab) from Pfizer in the 28 countries that form the European Economic Area (EEA). This deal strengthens the Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab.

The global adalimumab, infliximab and etanercept biosimilars market is segmented -

1) By Product: Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others), Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo).

2) By Application: Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, Ankylosing spondylitis, Plaque psoriasis, Others.

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

The major players covered in the global adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, Abbvie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd, Glenmark pharmaceuticals, Cipla Ltd, Emcure Pharmaceuticals Ltd.

The countries covered in the global adalimumab, infliximab and etanercept biosimilars market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The regions covered in the global adalimumab, infliximab and etanercept biosimilars market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    1. Executive Summary

    2. Adalimumab, Infliximab And Etanercept Biosimilars Market Characteristics

    3. Adalimumab, Infliximab And Etanercept Biosimilars Market Size And Growth

    3.1. Global Adalimumab, Infliximab And Etanercept Biosimilars Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Adalimumab, Infliximab And Etanercept Biosimilars Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation

    4.1. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others)

    Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola)

    Cipleumab (Erelzi, Eticovo)

    4.2. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Crohn’s disease

    Psoriatic arthritis

    Rheumatoid arthritis

    Ulcerative colitis

    Ankylosing spondylitis

    Plaque psoriasis

    Others

    4.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    5. Adalimumab, Infliximab And Etanercept Biosimilars Market Regional And Country Analysis

    5.1. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Adalimumab, Infliximab And Etanercept Biosimilars Market

    6.1. Asia-Pacific Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    6.2. Asia-Pacific Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Adalimumab, Infliximab And Etanercept Biosimilars Market

    7.1. China Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    7.2. China Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Adalimumab, Infliximab And Etanercept Biosimilars Market

    8.1. India Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    8.2. India Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Adalimumab, Infliximab And Etanercept Biosimilars Market

    9.1. Japan Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    9.2. Japan Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Adalimumab, Infliximab And Etanercept Biosimilars Market

    10.1. Australia Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Adalimumab, Infliximab And Etanercept Biosimilars Market

    11.1. Indonesia Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Adalimumab, Infliximab And Etanercept Biosimilars Market

    12.1. South Korea Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Adalimumab, Infliximab And Etanercept Biosimilars Market

    13.1. Western Europe Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    13.2. Western Europe Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Adalimumab, Infliximab And Etanercept Biosimilars Market

    14.1. UK Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    14.2. UK Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Adalimumab, Infliximab And Etanercept Biosimilars Market

    15.1. Germany Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Adalimumab, Infliximab And Etanercept Biosimilars Market

    16.3. France Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Adalimumab, Infliximab And Etanercept Biosimilars Market

    17.1. Eastern Europe Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    17.2. Eastern Europe Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Adalimumab, Infliximab And Etanercept Biosimilars Market

    18.1. Russia Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Adalimumab, Infliximab And Etanercept Biosimilars Market

    19.1. North America Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    19.2. North America Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Adalimumab, Infliximab And Etanercept Biosimilars Market

    20.1. USA Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    20.2. USA Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Adalimumab, Infliximab And Etanercept Biosimilars Market

    21.1. South America Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    21.2. South America Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Adalimumab, Infliximab And Etanercept Biosimilars Market

    22.1. Brazil Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Adalimumab, Infliximab And Etanercept Biosimilars Market

    23.1. Middle East Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    23.2. Middle East Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Adalimumab, Infliximab And Etanercept Biosimilars Market

    24.1. Africa Adalimumab, Infliximab And Etanercept Biosimilars Market Overview

    24.2. Africa Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Landscape And Company Profiles

    25.1. Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Landscape

    25.2. Adalimumab, Infliximab And Etanercept Biosimilars Market Company Profiles

    25.2.1. Zydus Cadila

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Sandoz (Novartis)

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Samsung Bioepis

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Abbvie

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Amgen

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Adalimumab, Infliximab And Etanercept Biosimilars Market

    27. Adalimumab, Infliximab And Etanercept Biosimilars Market Trends And Strategies

    28. Adalimumab, Infliximab And Etanercept Biosimilars Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: China, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: India, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: Japan, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: Australia, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: Indonesia, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: South Korea, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: Western Europe, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: UK, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Germany, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: France, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Eastern Europe, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: Russia, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: North America, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: USA, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: South America, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: Brazil, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: Middle East, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Africa, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: Zydus Cadila Financial Performance
  • Table 28: Sandoz (Novartis) Financial Performance
  • Table 29: Samsung Bioepis Financial Performance
  • Table 30: Abbvie Financial Performance
  • Table 31: Amgen Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: China, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: India, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: Japan, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: Australia, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: Indonesia, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: South Korea, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: Western Europe, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: UK, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Germany, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: France, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Eastern Europe, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: Russia, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: North America, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: USA, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: South America, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: Brazil, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: Middle East, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Africa, Adalimumab, Infliximab And Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: Zydus Cadila Financial Performance
  • Figure 28: Sandoz (Novartis) Financial Performance
  • Figure 29: Samsung Bioepis Financial Performance
  • Figure 30: Abbvie Financial Performance
  • Figure 31: Amgen Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)